What to watch as IDEAYA Biosciences reports OptimUM-02 topline results in uveal melanoma

IDEAYA Biosciences will report OptimUM-02 topline data on April 13. Read why this uveal melanoma trial could shift the treatment landscape.

IDEAYA Biosciences will report OptimUM-02 topline data on April 13. Read why this uveal melanoma trial could shift the treatment landscape.

IDEAYA Biosciences nears darovasertib trial data. Discover how results could reshape metastatic uveal melanoma treatment strategies.